person · Reporting owner

MURABITO JOHN M

Disclosed activity across 3 companies

Tapewire entity: 74221
SEC CIK: 0001126222

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Cigna GroupCI · Entity 550	EVP & Chief Admin Officer	March 01, 2022	March 03, 2022
WINNEBAGO INDUSTRIES INCWGO · Entity 5088	Director	October 14, 2025	October 16, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Cigna Group

Report date March 01, 2022 · Filed March 03, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $.01 Par ValueSEC Table I · non-derivative	Direct	51,226	Reported balance After 2022-03-01 transaction · row 1 1 source row Row 1 · 2022-03-01 · Tax withholding · Disposed 318 · Balance 51,226 F1: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares.
Common Stock, $.01 Par ValueSEC Table I · non-derivative	IndirectBy 401(k)	3,749.484	Reported balance Holding disclosure · report date 2022-03-01 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 3,749.484 F2: Represents shares acquired through ongoing participation in Cigna's 401(k) Plan.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares.

F2: Represents shares acquired through ongoing participation in Cigna's 401(k) Plan.

WINNEBAGO INDUSTRIES INC

Report date October 14, 2025 · Filed October 16, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $.50 par valueSEC Table I · non-derivative	Direct	25,668	Reported balance After 2025-10-14 transaction · row 1 1 source row Row 1 · 2025-10-14 · Grant · Acquired 4,878 · Balance 25,668 F1: Annual Restricted Stock Unit (RSU) Award granted under the Winnebago Industries, Inc. Amended and Restated 2019 Omnibus Incentive Plan. The restricted stock units vest one year from the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: Annual Restricted Stock Unit (RSU) Award granted under the Winnebago Industries, Inc. Amended and Restated 2019 Omnibus Incentive Plan. The restricted stock units vest one year from the date of grant.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Cigna Holding Co

Report date December 20, 2018 · Filed December 26, 2018

Section 16 reporting ended · disclosed 2018-12-26. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common Stock, $.25 Par ValueSEC Table I · non-derivative	Direct	Reported balance After 2018-12-20 transaction · row 1 1 source row Row 1 · 2018-12-20 · Disposition to issuer · Disposed 65,521 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.
Common Stock, $.25 Par ValueSEC Table I · non-derivative	IndirectBy 401(k)	Reported balance After 2018-12-20 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2018-12-20 · Disposition to issuer · Disposed 3,508.5753 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F8: Represents shares acquired through ongoing participation in Cigna's 401(k) Plan and disposed of in connection with the Merger.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $120.90 · Expires 2025-02-25	Direct	Reported balance After 2018-12-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-12-20 · Disposition to issuer · Disposed 15,802 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F3: This option was fully vested and exercisable at the time of the Merger.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $139.22 · Expires 2026-03-01	Direct	Reported balance After 2018-12-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-12-20 · Disposition to issuer · Disposed 15,054 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F5: Two-thirds of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $139.22 per share, with the remaining one-third of the option vesting on March 1, 2019.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $149.14 · Expires 2027-02-28	Direct	Reported balance After 2018-12-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-12-20 · Disposition to issuer · Disposed 12,402 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F6: One-third of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $149.135 per share, with the remaining two-thirds of the option vesting in two equal installments on February 28, 2019 and February 28, 2020.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $197.35 · Expires 2028-02-28	Direct	Reported balance After 2018-12-20 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-12-20 · Disposition to issuer · Disposed 9,739 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F7: This option, which would have vested in three equal installments beginning on February 28, 2019, was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $197.35 per share on the same vesting terms.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote)

F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F3: This option was fully vested and exercisable at the time of the Merger.

F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option.

F5: Two-thirds of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $139.22 per share, with the remaining one-third of the option vesting on March 1, 2019.

F6: One-third of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $149.135 per share, with the remaining two-thirds of the option vesting in two equal installments on February 28, 2019 and February 28, 2020.

F7: This option, which would have vested in three equal installments beginning on February 28, 2019, was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $197.35 per share on the same vesting terms.

F8: Represents shares acquired through ongoing participation in Cigna's 401(k) Plan and disposed of in connection with the Merger.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 14, 2025 Filed Oct 16, 2025 16:41 UTC	WINNEBAGO INDUSTRIES INC WGO · Entity 5088	GrantCommon Stock, $.50 par value	4,878	$0.00	$0.00	Disclosure SEC source: 0001126222-25-000004 · form4-10162025_041020.xml · nonDerivative · entry 1 MURABITO JOHN M · CIK 0001126222 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,668 F1 · shares: Annual Restricted Stock Unit (RSU) Award granted under the Winnebago Industries, Inc. Amended and Restated 2019 Omnibus Incentive Plan. The restricted stock units vest one year from the date of grant. Read SEC document
October 15, 2024 Filed Oct 17, 2024 14:45 UTC	WINNEBAGO INDUSTRIES INC WGO · Entity 5088	GrantCommon Stock, $.50 par value	2,548	$0.00	$0.00	Disclosure SEC source: 0001415889-24-025254 · form4-10172024_021014.xml · nonDerivative · entry 1 MURABITO JOHN M · CIK 0001126222 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,790 F1 · shares: Granted under the Winnebago Industries, Inc. 2019 Omnibus Incentive Plan. The restricted stock units vest one year from the date of grant. Read SEC document
October 10, 2023 Filed Oct 12, 2023 18:38 UTC	WINNEBAGO INDUSTRIES INC WGO · Entity 5088	GrantCommon Stock, $.50 par value	2,556	$0.00	$0.00	Disclosure SEC source: 0001415889-23-014118 · form4-10122023_061018.xml · nonDerivative · entry 1 MURABITO JOHN M · CIK 0001126222 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,242 F1 · shares: Granted under the Winnebago Industries, Inc. 2019 Omnibus Incentive Plan. The restricted stock units vest one year from the date of grant. Read SEC document
October 11, 2022 Filed Oct 13, 2022 20:44 UTC	WINNEBAGO INDUSTRIES INC WGO · Entity 5088	GrantCommon Stock, $.50 par value	2,229	$0.00	$0.00	Disclosure SEC source: 0001415889-22-010502 · form4-10132022_011050.xml · nonDerivative · entry 1 MURABITO JOHN M · CIK 0001126222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,686 F1 · shares: Granted under the Winnebago Industries, Inc. 2019 Omnibus Incentive Plan. The restricted stock units vest one year from the date of grant. Read SEC document
March 01, 2022 Filed Mar 3, 2022 17:28 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	318	$236.48	$75,200.64	Disclosure SEC source: 0001225208-22-004172 · doc4.xml · nonDerivative · entry 1 MURABITO JOHN M · CIK 0001126222 · EVP & Chief Admin Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,226 F1 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document
February 25, 2022 Filed Mar 1, 2022 20:18 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	711	$229.64	$163,274.04	Disclosure SEC source: 0001225208-22-003751 · doc4.xml · nonDerivative · entry 3 MURABITO JOHN M · CIK 0001126222 · EVP & Chief Admin Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,544 F3 · shares: Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares. Read SEC document
February 25, 2022 Filed Mar 1, 2022 20:18 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	483	$229.64	$110,916.12	Disclosure SEC source: 0001225208-22-003751 · doc4.xml · nonDerivative · entry 2 MURABITO JOHN M · CIK 0001126222 · EVP & Chief Admin Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,255 F2 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document
February 25, 2022 Filed Mar 1, 2022 20:18 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	2,294	$0.00	$0.00	Disclosure SEC source: 0001225208-22-003751 · doc4.xml · nonDerivative · entry 1 MURABITO JOHN M · CIK 0001126222 · EVP & Chief Admin Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,738 F1 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2019-2021 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document
February 23, 2022 Filed Feb 25, 2022 20:49 UTC	Cigna Group CI · Entity 550	GrantEmployee Stock Option (Right to Buy) · Derivative	10,247	$0.00 Strike: $227.02	$0.00	Disclosure SEC source: 0001225208-22-003486 · doc4.xml · derivative · entry 3 MURABITO JOHN M · CIK 0001126222 · EVP & Chief Admin Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,247 Underlying: Common Stock, $.01 Par Value · 10,247 shares Expires 2032-02-23 F3 · derivative.exercise_date: This option vests in three equal annual installments beginning March 1, 2023. Read SEC document
February 23, 2022 Filed Feb 25, 2022 20:49 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	2,286	$0.00	$0.00	Disclosure SEC source: 0001225208-22-003486 · doc4.xml · nonDerivative · entry 1 MURABITO JOHN M · CIK 0001126222 · EVP & Chief Admin Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,444 F1 · shares: These restricted shares vest in three equal annual installments beginning March 1, 2023. Read SEC document
October 12, 2021 Filed Oct 14, 2021 18:34 UTC	WINNEBAGO INDUSTRIES INC WGO · Entity 5088	GrantCommon Stock, $.50 par value	1,654	$0.00	$0.00	Disclosure SEC source: 0001179110-21-009402 · edgar.xml · nonDerivative · entry 1 MURABITO JOHN M · CIK 0001126222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,457 F1 · shares: Granted under the Winnebago Industries, Inc. 2019 Omnibus Incentive Plan. The restricted stock units vest one year from the date of grant. Read SEC document
February 26, 2021 Filed Mar 2, 2021 20:28 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	983	$210.31	$206,734.73	Disclosure SEC source: 0001225208-21-004367 · doc4.xml · nonDerivative · entry 3 MURABITO JOHN M · CIK 0001126222 · EVP, HR & Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,158 F3 · shares: Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares. Read SEC document
February 26, 2021 Filed Mar 2, 2021 20:28 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	483	$210.31	$101,579.73	Disclosure SEC source: 0001225208-21-004367 · doc4.xml · nonDerivative · entry 2 MURABITO JOHN M · CIK 0001126222 · EVP, HR & Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,141 F2 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document
February 26, 2021 Filed Mar 2, 2021 20:28 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	3,167	$0.00	$0.00	Disclosure SEC source: 0001225208-21-004367 · doc4.xml · nonDerivative · entry 1 MURABITO JOHN M · CIK 0001126222 · EVP, HR & Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,624 F1 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2018-2020 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document
February 24, 2021 Filed Feb 26, 2021 20:22 UTC	Cigna Group CI · Entity 550	GrantEmployee Stock Option (Right to Buy) · Derivative	12,150	$0.00 Strike: $213.80	$0.00	Disclosure SEC source: 0001225208-21-003976 · doc4.xml · derivative · entry 3 MURABITO JOHN M · CIK 0001126222 · EVP, HR & Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,150 Underlying: Common Stock, $.01 Par Value · 12,150 shares Expires 2031-02-24 F3 · derivative.exercise_date: This option vests in three equal annual installments beginning March 1, 2022. Read SEC document
February 24, 2021 Filed Feb 26, 2021 20:22 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	2,548	$0.00	$0.00	Disclosure SEC source: 0001225208-21-003976 · doc4.xml · nonDerivative · entry 1 MURABITO JOHN M · CIK 0001126222 · EVP, HR & Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,457 F1 · shares: These restricted shares vest in three equal annual installments beginning March 1, 2022. Read SEC document
December 18, 2020 Filed Dec 21, 2020 17:50 UTC	Cigna Group CI · Entity 550	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	1,816	$0.00 Strike: $120.90	$0.00	Disclosure SEC source: 0001225208-20-014949 · doc4.xml · derivative · entry 6 MURABITO JOHN M · CIK 0001126222 · EVP, HR & Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.01 Par Value · 1,816 shares Expires 2025-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2020. F3 · derivative.exercise_date: This option was granted on February 25, 2015. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document
December 18, 2020 Filed Dec 21, 2020 17:50 UTC	Cigna Group CI · Entity 550	Exercise / conversionCommon Stock, $.01 Par Value	1,816	$120.90	$219,545.32	Disclosure SEC source: 0001225208-20-014949 · doc4.xml · nonDerivative · entry 3 MURABITO JOHN M · CIK 0001126222 · EVP, HR & Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2020. Read SEC document
December 17, 2020 Filed Dec 21, 2020 17:50 UTC	Cigna Group CI · Entity 550	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	13,986	$0.00 Strike: $120.90	$0.00	Disclosure SEC source: 0001225208-20-014949 · doc4.xml · derivative · entry 5 MURABITO JOHN M · CIK 0001126222 · EVP, HR & Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,816 Underlying: Common Stock, $.01 Par Value · 13,986 shares Expires 2025-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2020. F3 · derivative.exercise_date: This option was granted on February 25, 2015. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document
December 17, 2020 Filed Dec 21, 2020 17:50 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	13,986	$203.31	$2,843,493.66	Disclosure SEC source: 0001225208-20-014949 · doc4.xml · nonDerivative · entry 2 MURABITO JOHN M · CIK 0001126222 · EVP, HR & Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,093 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2020. Read SEC document
December 17, 2020 Filed Dec 21, 2020 17:50 UTC	Cigna Group CI · Entity 550	Exercise / conversionCommon Stock, $.01 Par Value	13,986	$120.90	$1,690,837.47	Disclosure SEC source: 0001225208-20-014949 · doc4.xml · nonDerivative · entry 1 MURABITO JOHN M · CIK 0001126222 · EVP, HR & Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,079 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2020. Read SEC document
November 04, 2020 Filed Nov 6, 2020 18:44 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	14,669	$210.00	$3,080,490.00	Disclosure SEC source: 0001225208-20-013210 · doc4.xml · nonDerivative · entry 1 MURABITO JOHN M · CIK 0001126222 · EVP, HR & Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,093 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. Read SEC document
October 13, 2020 Filed Oct 15, 2020 19:46 UTC	WINNEBAGO INDUSTRIES INC WGO · Entity 5088	GrantCommon Stock, par value $.50	2,019	$0.00	$0.00	Disclosure SEC source: 0001179110-20-010466 · edgar.xml · nonDerivative · entry 1 MURABITO JOHN M · CIK 0001126222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,803 F1 · shares: Granted under the Winnebago Industries, Inc. 2019 Omnibus Incentive Plan. The restricted stock units vest one year from the date of grant. Read SEC document
June 08, 2020 Filed Jun 9, 2020 18:18 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	4,338	$215.00	$932,670.00	Disclosure SEC source: 0001225208-20-008774 · doc4.xml · nonDerivative · entry 1 MURABITO JOHN M · CIK 0001126222 · EVP, HR & Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,762 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 20, 2019. Read SEC document
March 04, 2020 Filed Mar 6, 2020 17:13 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	5,000	$210.00	$1,050,000.00	Disclosure SEC source: 0001225208-20-004599 · doc4.xml · nonDerivative · entry 1 MURABITO JOHN M · CIK 0001126222 · EVP, HR & Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,100 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 20, 2019. Read SEC document
February 28, 2020 Filed Mar 2, 2020 20:47 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	1,358	$179.41	$243,638.78	Disclosure SEC source: 0001225208-20-003959 · doc4.xml · nonDerivative · entry 3 MURABITO JOHN M · CIK 0001126222 · EVP, HR & Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,100 F3 · shares: Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares. Read SEC document
February 28, 2020 Filed Mar 2, 2020 20:47 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	4,384	$0.00	$0.00	Disclosure SEC source: 0001225208-20-003959 · doc4.xml · nonDerivative · entry 2 MURABITO JOHN M · CIK 0001126222 · EVP, HR & Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,458 F2 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2017-2019 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document
February 27, 2020 Filed Mar 2, 2020 20:47 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	239	$185.76	$44,396.64	Disclosure SEC source: 0001225208-20-003959 · doc4.xml · nonDerivative · entry 1 MURABITO JOHN M · CIK 0001126222 · EVP, HR & Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,074 F1 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document
February 26, 2020 Filed Feb 28, 2020 21:27 UTC	Cigna Group CI · Entity 550	GrantEmployee Stock Option (Right to Buy) · Derivative	8,578	$0.00 Strike: $192.02	$0.00	Disclosure SEC source: 0001225208-20-003812 · doc4.xml · derivative · entry 3 MURABITO JOHN M · CIK 0001126222 · EVP, HR & Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,578 Underlying: Common Stock, $.01 Par Value · 8,578 shares Expires 2030-02-26 F3 · derivative.exercise_date: This option vests in three equal annual installments beginning February 26, 2021. Read SEC document
February 26, 2020 Filed Feb 28, 2020 21:27 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	2,344	$0.00	$0.00	Disclosure SEC source: 0001225208-20-003812 · doc4.xml · nonDerivative · entry 1 MURABITO JOHN M · CIK 0001126222 · EVP, HR & Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,313 F1 · shares: These restricted shares vests in three equal annual installments beginning February 26, 2021. Read SEC document
February 24, 2020 Filed Feb 26, 2020 17:35 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	10,000	$209.00	$2,090,000.00	Disclosure SEC source: 0001225208-20-003583 · doc4.xml · nonDerivative · entry 1 MURABITO JOHN M · CIK 0001126222 · EVP, HR & Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,969 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 20, 2019. Read SEC document
October 09, 2019 Filed Oct 11, 2019 17:07 UTC	WINNEBAGO INDUSTRIES INC WGO · Entity 5088	GrantCommon Stock, $.50 par value	2,947	$0.00	$0.00	Disclosure SEC source: 0001179110-19-010928 · edgar.xml · nonDerivative · entry 1 MURABITO JOHN M · CIK 0001126222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,784 F1 · shares: Granted under the Winnebago Industries, Inc. 2019 Omnibus Incentive Plan. The restricted stock units vest one year from the date of grant. Read SEC document
March 01, 2019 Filed Mar 5, 2019 21:24 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	1,445	$177.85	$256,993.25	Disclosure SEC source: 0001225208-19-004747 · doc4.xml · nonDerivative · entry 2 MURABITO JOHN M · CIK 0001126222 · EVP, HR & Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,969 F2 · shares: Represents shares withheld to satisfy tax obligations upon vesting. Read SEC document
March 01, 2019 Filed Mar 5, 2019 21:24 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	4,644	$0.00	$0.00	Disclosure SEC source: 0001225208-19-004747 · doc4.xml · nonDerivative · entry 1 MURABITO JOHN M · CIK 0001126222 · EVP, HR & Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,414 F1 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2016-2018 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document
February 27, 2019 Filed Mar 1, 2019 20:22 UTC	Cigna Group CI · Entity 550	GrantEmployee Stock Option (Right to Buy) · Derivative	7,768	$0.00 Strike: $183.44	$0.00	Disclosure SEC source: 0001225208-19-004240 · doc4.xml · derivative · entry 3 MURABITO JOHN M · CIK 0001126222 · EVP, HR & Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,768 Underlying: Common Stock, $.01 Par Value · 7,768 shares Expires 2029-02-27 F3 · derivative.exercise_date: This option vests in three equal annual installments beginning February 27, 2020. Read SEC document
February 27, 2019 Filed Mar 1, 2019 20:22 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	2,249	$0.00	$0.00	Disclosure SEC source: 0001225208-19-004240 · doc4.xml · nonDerivative · entry 1 MURABITO JOHN M · CIK 0001126222 · EVP, HR & Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,770 F1 · shares: These restricted shares vest in three equal annual installments beginning February 27, 2020. Read SEC document
December 20, 2018 Filed Dec 26, 2018 18:43 UTC	Cigna Holding Co CI · Entity 161580	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	9,739	Not disclosed Strike: $197.35	Not disclosed	Disclosure SEC source: 0001567619-18-008653 · doc1.xml · derivative · entry 6 MURABITO JOHN M · CIK 0001126222 · EVP, HR & Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.25 Par Value · 9,739 shares Expires 2028-02-28 F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2 · kind: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F7 · derivative.exercise_date: This option, which would have vested in three equal installments beginning on February 28, 2019, was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $197.35 per share on the same vesting terms. Read SEC document
December 20, 2018 Filed Dec 26, 2018 18:43 UTC	Cigna Holding Co CI · Entity 161580	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	12,402	Not disclosed Strike: $149.14	Not disclosed	Disclosure SEC source: 0001567619-18-008653 · doc1.xml · derivative · entry 5 MURABITO JOHN M · CIK 0001126222 · EVP, HR & Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.25 Par Value · 12,402 shares Expires 2027-02-28 F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2 · kind: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F6 · derivative.exercise_date: One-third of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $149.135 per share, with the remaining two-thirds of the option vesting in two equal installments on February 28, 2019 and February 28, 2020. Read SEC document
December 20, 2018 Filed Dec 26, 2018 18:43 UTC	Cigna Holding Co CI · Entity 161580	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	15,054	Not disclosed Strike: $139.22	Not disclosed	Disclosure SEC source: 0001567619-18-008653 · doc1.xml · derivative · entry 4 MURABITO JOHN M · CIK 0001126222 · EVP, HR & Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.25 Par Value · 15,054 shares Expires 2026-03-01 F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2 · kind: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F5 · derivative.exercise_date: Two-thirds of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $139.22 per share, with the remaining one-third of the option vesting on March 1, 2019. Read SEC document
December 20, 2018 Filed Dec 26, 2018 18:43 UTC	Cigna Holding Co CI · Entity 161580	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	15,802	Not disclosed Strike: $120.90	Not disclosed	Disclosure SEC source: 0001567619-18-008653 · doc1.xml · derivative · entry 3 MURABITO JOHN M · CIK 0001126222 · EVP, HR & Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.25 Par Value · 15,802 shares Expires 2025-02-25 F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2 · kind: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F3 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger. Read SEC document
December 20, 2018 Filed Dec 26, 2018 18:43 UTC	Cigna Holding Co CI · Entity 161580	Disposition to issuerCommon Stock, $.25 Par Value	3,508.5753	$0.00	$0.00	Disclosure SEC source: 0001567619-18-008653 · doc1.xml · nonDerivative · entry 2 MURABITO JOHN M · CIK 0001126222 · EVP, HR & Services 10b5-1 filing: Not disclosed Ownership: Indirect · By 401(k) Disclosed balance after: 0 F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2 · kind: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F8 · shares: Represents shares acquired through ongoing participation in Cigna's 401(k) Plan and disposed of in connection with the Merger. F1 · price: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2 · price: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. Read SEC document
December 20, 2018 Filed Dec 26, 2018 18:43 UTC	Cigna Holding Co CI · Entity 161580	Disposition to issuerCommon Stock, $.25 Par Value	65,521	$0.00	$0.00	Disclosure SEC source: 0001567619-18-008653 · doc1.xml · nonDerivative · entry 1 MURABITO JOHN M · CIK 0001126222 · EVP, HR & Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2 · kind: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F1 · price: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2 · price: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. Read SEC document
December 20, 2018 Filed Dec 26, 2018 19:17 UTC	Cigna Group CI · Entity 550	GrantEmployee Stock Option (Right to Buy) · Derivative	9,739	Not disclosed Strike: $197.35	Not disclosed	Disclosure SEC source: 0001567619-18-008706 · doc1.xml · derivative · entry 6 MURABITO JOHN M · CIK 0001126222 · EVP, HR & Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,739 Underlying: Common Stock, $0.01 Par Value · 9,739 shares Expires 2028-02-28 F1 · kind: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F5 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F8 · derivative.exercise_date: This option, which would have vested in three equal installments beginning on February 28, 2019, was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $197.35 per share on the same vesting terms. Read SEC document
December 20, 2018 Filed Dec 26, 2018 19:17 UTC	Cigna Group CI · Entity 550	GrantEmployee Stock Option (Right to Buy) · Derivative	12,402	Not disclosed Strike: $149.14	Not disclosed	Disclosure SEC source: 0001567619-18-008706 · doc1.xml · derivative · entry 5 MURABITO JOHN M · CIK 0001126222 · EVP, HR & Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,402 Underlying: Common Stock, $0.01 Par Value · 12,402 shares Expires 2027-02-28 F1 · kind: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F5 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F7 · derivative.exercise_date: One-third of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $149.135 per share, with the remaining two-thirds of the option vesting in two equal installments on February 28, 2019 and February 28, 2020. Read SEC document
December 20, 2018 Filed Dec 26, 2018 19:17 UTC	Cigna Group CI · Entity 550	GrantEmployee Stock Option (Right to Buy) · Derivative	15,054	Not disclosed Strike: $139.22	Not disclosed	Disclosure SEC source: 0001567619-18-008706 · doc1.xml · derivative · entry 4 MURABITO JOHN M · CIK 0001126222 · EVP, HR & Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,054 Underlying: Common Stock, $0.01 Par Value · 15,054 shares Expires 2026-03-01 F1 · kind: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F5 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F6 · derivative.exercise_date: Two-thirds of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $139.22 per share, with the remaining one-third of the option vesting on March 1, 2019. Read SEC document
December 20, 2018 Filed Dec 26, 2018 19:17 UTC	Cigna Group CI · Entity 550	GrantEmployee Stock Option (Right to Buy) · Derivative	15,802	Not disclosed Strike: $120.90	Not disclosed	Disclosure SEC source: 0001567619-18-008706 · doc1.xml · derivative · entry 3 MURABITO JOHN M · CIK 0001126222 · EVP, HR & Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,802 Underlying: Common Stock, $0.01 Par Value · 15,802 shares Expires 2025-02-25 F1 · kind: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F5 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F4 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger. Read SEC document
December 20, 2018 Filed Dec 26, 2018 19:17 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $0.01 Par Value	3,508.5753	$0.00	$0.00	Disclosure SEC source: 0001567619-18-008706 · doc1.xml · nonDerivative · entry 2 MURABITO JOHN M · CIK 0001126222 · EVP, HR & Services 10b5-1 filing: Not disclosed Ownership: Indirect · By 401(k) Disclosed balance after: 3,508.5753 F1 · kind: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F3 · shares: Represents shares acquired through ongoing participation in Cigna's 401(k) Plan and converted into an equivalent number of shares of New Cigna's Common Stock in connection with the Merger. F1 · price: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. Read SEC document
December 20, 2018 Filed Dec 26, 2018 19:17 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $0.01 Par Value	65,521	$0.00	$0.00	Disclosure SEC source: 0001567619-18-008706 · doc1.xml · nonDerivative · entry 1 MURABITO JOHN M · CIK 0001126222 · EVP, HR & Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,521 F1 · kind: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F1 · price: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. Read SEC document
October 15, 2018 Filed Oct 16, 2018 21:21 UTC	WINNEBAGO INDUSTRIES INC WGO · Entity 5088	GrantCommon Stock, $.50 par value	2,997	$0.00	$0.00	Disclosure SEC source: 0000897101-18-000980 · ownership.xml · nonDerivative · entry 1 MURABITO JOHN M · CIK 0001126222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,837 F1 · shares: Granted under the Winnebago Industries, Inc. 2014 Omnibus Equity, Performance Awards, and Incentive Plan. Restricted awards are vested upon termination of services as a director. Read SEC document
March 02, 2018 Filed Mar 6, 2018 18:41 UTC	Cigna Holding Co CI · Entity 161580	Tax withholdingCommon Stock, $.25 Par Value	3,056	$192.44	$588,096.64	Disclosure SEC source: 0001225208-18-005497 · doc4.xml · nonDerivative · entry 2 MURABITO JOHN M · CIK 0001126222 · EVP, HR & Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,521 F2 · shares: Represents shares withheld to satisfy tax obligations upon vesting. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.